Repros Therapeutics Continues Higher (RPRX)

Repros Therapeutics Inc. RPRX continues to move higher in the session, and is now up 67% on more than 4.4 million shares. It had been as high as $2.53 during the session, but has since come back down to $2.36. Repros Therapeutics focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders.